STN: BL 103665
Proper Name: Coagulation Factor VIIa (Recombinant)
Manufacturer: Novo Nordisk Inc, License #1261
- Treatment of bleeding episodes and peri-operative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.
- Treatment of bleeding episodes and peri-operative management in adults with acquired hemophilia.
FDA Online Label Repository
Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.
FDA Approves New Formulation of Coagulation Therapy[ARCHIVED]
Press Release: May 9, 2008